These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 20570112)

  • 21. Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts.
    Maenhout SK; Van Lint S; Emeagi PU; Thielemans K; Aerts JL
    Int J Cancer; 2014 Mar; 134(5):1077-90. PubMed ID: 23983191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms.
    Lizée G; Radvanyi LG; Overwijk WW; Hwu P
    Clin Cancer Res; 2006 Aug; 12(16):4794-803. PubMed ID: 16914564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcription factors in myeloid-derived suppressor cell recruitment and function.
    Sonda N; Chioda M; Zilio S; Simonato F; Bronte V
    Curr Opin Immunol; 2011 Apr; 23(2):279-85. PubMed ID: 21227670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myeloid-derived suppressor cells contribute to oral cancer progression in 4NQO-treated mice.
    Chu M; Su YX; Wang L; Zhang TH; Liang YJ; Liang LZ; Liao GQ
    Oral Dis; 2012 Jan; 18(1):67-73. PubMed ID: 21883708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.
    Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T
    J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloid-derived suppressor cells in cancer: recent progress and prospects.
    Khaled YS; Ammori BJ; Elkord E
    Immunol Cell Biol; 2013 Sep; 91(8):493-502. PubMed ID: 23797066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insights into Myeloid-Derived Suppressor Cells in Inflammatory Diseases.
    Kwak Y; Kim HE; Park SG
    Arch Immunol Ther Exp (Warsz); 2015 Aug; 63(4):269-85. PubMed ID: 25990434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors.
    Seliger B; Massa C; Rini B; Ko J; Finke J
    Trends Mol Med; 2010 Apr; 16(4):184-92. PubMed ID: 20304705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The roles of myeloid-derived suppressor cells in transplantation.
    Wu T; Zhao Y; Zhao Y
    Expert Rev Clin Immunol; 2014 Oct; 10(10):1385-94. PubMed ID: 25119260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A copper chelate selectively triggers apoptosis in myeloid-derived suppressor cells in a drug-resistant tumor model and enhances antitumor immune response.
    Chakraborty P; Das S; Banerjee K; Sinha A; Roy S; Chatterjee M; Choudhuri SK
    Immunopharmacol Immunotoxicol; 2014 Apr; 36(2):165-75. PubMed ID: 24611750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune responses in hepatocellular carcinoma.
    Korangy F; Höchst B; Manns MP; Greten TF
    Dig Dis; 2010; 28(1):150-4. PubMed ID: 20460904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells.
    Yang R; Cai Z; Zhang Y; Yutzy WH; Roby KF; Roden RB
    Cancer Res; 2006 Jul; 66(13):6807-15. PubMed ID: 16818658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy.
    Talmadge JE
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5243-8. PubMed ID: 17875751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.
    Lee SY; Choi HK; Lee KJ; Jung JY; Hur GY; Jung KH; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Yoo SH
    J Immunother; 2009 Jan; 32(1):22-8. PubMed ID: 19307990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis.
    Sinha P; Clements VK; Ostrand-Rosenberg S
    Cancer Res; 2005 Dec; 65(24):11743-51. PubMed ID: 16357187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells.
    Bianchi G; Borgonovo G; Pistoia V; Raffaghello L
    Histol Histopathol; 2011 Jul; 26(7):941-51. PubMed ID: 21630223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myeloid cell population dynamics in healthy and tumor-bearing mice.
    Ueha S; Shand FH; Matsushima K
    Int Immunopharmacol; 2011 Jul; 11(7):783-8. PubMed ID: 21406269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myeloid-derived suppressor cells: paradoxical roles in infection and immunity.
    Dai J; El Gazzar M; Li GY; Moorman JP; Yao ZQ
    J Innate Immun; 2015; 7(2):116-26. PubMed ID: 25401944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloid-derived suppressor cells in cancer patients: a clinical perspective.
    Montero AJ; Diaz-Montero CM; Kyriakopoulos CE; Bronte V; Mandruzzato S
    J Immunother; 2012; 35(2):107-15. PubMed ID: 22306898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers.
    Huang B; Lei Z; Zhao J; Gong W; Liu J; Chen Z; Liu Y; Li D; Yuan Y; Zhang GM; Feng ZH
    Cancer Lett; 2007 Jul; 252(1):86-92. PubMed ID: 17257744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.